Search results for "THROMBOEMBOLISM"

showing 10 items of 208 documents

Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normali…

2012

Subtherapeutic international normalized ratio (INR) is frequently encountered in clinical practice, and patients with high-risk atrial fibrillation (AF) and with mechanical heart valve (MHV) with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events (TE). However, there are no prospective data evaluating this risk. Consecutive patients with a history of stable anticoagulation, but with a subtherapeutic INR, were prospectively included. Data on use and dose of low-molecular weight heparin (LMWH) bridging therapy were collected. The incidence of objectively confirmed TE and of major bleeding events within 90 days after the index INR was assessed. Five hundred…

MaleRiskmedicine.medical_specialtyPopulationvenous thromboembolismHemorrhageComorbidityThrombophiliaFollow-Up StudiePostoperative ComplicationsInternal medicineThromboembolismAtrial FibrillationmedicineHumansThrombophiliaProspective StudiesInternational Normalized RatioeducationProspective cohort studyAgedAged 80 and overHeart Valve Prosthesis Implantationeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceMedicine (all)WarfarinAnticoagulantAnticoagulantsAtrial fibrillationHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseConfidence intervalSurgeryProspective StudieHeart Valve ProsthesiHeart Valve ProsthesisFemalePostoperative ComplicationWarfarinbusinessCohort studymedicine.drugFollow-Up StudiesHuman
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study

2015

Abstract Background It is well known that atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with a higher risk of stroke, and new evidence links AF to cognitive impairment, independently from an overt stroke (CI). Our aim was to investigate, assuming an underlying role of atrial microembolism, the impact of CI and CKD in elderly hospitalized patients with AF. Methods We retrospectively analyzed the data collected on elderly patients in 66 Italian hospitals, in the frame of the REPOSI project. We analyzed the clinical characteristics of patients with AF and different degrees of CI. Multivariate logistic analysis was used to explore the relationship between variables an…

MaleSettore MED/09 - Medicina InternaREPOSI studyKidneyDisability EvaluationRetrospective StudieRisk Factorshospitalized patientAtrial Fibrillation80 and overOdds RatioLS4_4Renal InsufficiencyChronicMultivariate AnalysiStrokeAged 80 and overMedicine (all)BrainAtrial fibrillationStrokeFemaleatrial microembolismHumanGlomerular Filtration Ratemedicine.medical_specialtySocio-culturaleRenal functionelderlyCognition DisorderInternal medicineThromboembolismmedicineInternal MedicineHumansRenal insufficiency chronicHeart AtriaIntensive care medicineAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; ThromboembolismAgedRetrospective Studiesbusiness.industryRisk FactorSettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studyOdds ratiomedicine.diseaseAtrial fibrillationBlood pressureHeart failureMultivariate AnalysisAged Anticoagulants Atrial fibrillation Dementia Renal insufficiency chronic Stroke.Aged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Strokeatrial microembolism; elderly; hospitalized patients; REPOSI study;DementiabusinessCognition DisordersKidney diseaseAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; Thromboembolism; Internal Medicine; Medicine (all)
researchProduct

Prophylaxis of venous thromboembolism in elderly patients with multimorbidity

2013

none 327 si Pharmacological thromboprophylaxis (TP) is known to reduce venous thromboembolism (VTE) in medical inpatients, but the criteria for risk-driven prescription, safety and impact on mortality are still debated. We analyze data on elderly patients with multimorbidities admitted in the year 2010 to the Italian internal medicine wards participating in the REPOSI registry to investigate the rate of TP during the hospital stay, and analyze the factors that are related to its prescription. Multivariate logistic regression, area under the ROC curve and CART analysis were performed to look for independent predictors of TP prescription. Association between TP and VTE, bleeding and death in …

MaleTVPSettore MED/09 - Medicina InternaComorbidityLogistic regressionFondaparinuxVENOUS THROMBOEMBOLISM; THROMBOPROPHYLAXIS; Medical PatientsMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency MedicineThromboprophylaxis Venous thromboembolism Medical patients80 and overHospital MortalityAged 80 and overSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged; 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency Medicineprophylaxis; venous thromboembolism; elderlyHospitalizationArea Under CurveEmergency MedicineFemaleprophylaxismedicine.drugVenous thromboembolismmedicine.medical_specialtyThromboprophylaxis; Venous thromboembolismmultimorbidityBarthel indexvenous thromboembolismMEDLINEMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Emergency Medicine; Internal Medicineelderly patientselderlyMedical patientsInternal medicineInternal MedicinemedicineHumansMedical prescriptionprophylaxis; venous thromboembolism; elderly patientsPropensity ScoreIntensive care medicineThromboprophylaxisAgedbusiness.industryprophylaxiMedical patients; Thromboprophylaxis; Venous thromboembolismprophylaxis; Venous thromboembolism; Elderly; multimorbidity; medical patients; thromboprophylaxismedicine.diseaseComorbidityLogistic ModelsPropensity score matchingbusinessVenous thromboembolism
researchProduct

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study

2017

Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death. SUMMARY Background Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives To investigate the course of iSVT in the setting of an observational multicenter study. Methods We collected longitudinal data of 411 consecutive outpati…

MaleTime FactorsSuperficial vein thrombosisDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsInterquartile rangecohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; Adult; Aged; Anticoagulants; Cause of Death; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Lower Extremity; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Proportional Hazards Models; Pulmonary Embolism; Recurrence; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Venous ThrombosisCause of DeathNeoplasmssuperficial vein thrombosiOdds RatioLongitudinal StudiesCause of deathVenous ThrombosisIncidenceAnticoagulantHematologyMiddle AgedThrombosisPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureItalyLower Extremity030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtymedicine.drug_classvenous thromboembolismHemorrhage03 medical and health sciencesSex FactorsdeathInternal medicinesuperficial vein thrombosiscohort studymedicineHumansAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryAnticoagulantsmedicine.diseaseSurgerymajor bleedingMultivariate AnalysisPulmonary Embolismbusinesscohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; HematologyJournal of Thrombosis and Haemostasis
researchProduct

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemother…

2017

Background: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. Methods: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible. Those with incomplete or miscoded data were excluded. Khorana scores were calculated based on the pretreatment data and categorized into high (≥3) or intermediate (1-2) VTE risk. Other patient-, tumor-, and therapy-related factor…

MaleUrologic Neoplasmsmedicine.medical_specialtyMetastatic Urothelial Carcinomamedicine.medical_treatmentvenous thromboembolismAntineoplastic AgentsKhorana score030204 cardiovascular system & hematologyUrologic NeoplasmschemotherapyGastroenterologyArticleLeukocyte Count03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPredictive Value of TestsRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesLeukocytosisNeoplasm MetastasisAgedRetrospective StudiesChemotherapyBladder cancerbusiness.industryCancerRetrospective cohort studyHematologyGeneral MedicineMiddle Agedequipment and suppliesmedicine.disease3. Good healthSurgeryleukocytosisCardiovascular Diseases030220 oncology & carcinogenesisPredictive value of testsbladder cancerFemaleUrotheliummedicine.symptombusinessClinical and Applied Thrombosis/Hemostasis
researchProduct

Reply to e.g. Urrego et Al.

2015

MaleVenous ThrombosisCancer ResearchOncologybusiness.industryNeoplasmsMedicineHumansFemaleVenous ThromboembolismHeparin Low-Molecular-WeightbusinessHumanitiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2013

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyMESH: Intention to Treat AnalysisMESH: Venous Thromboembolism0302 clinical medicineMESH: Aged 80 and overRecurrence030212 general & internal medicineMESH: WarfarinAged 80 and overMESH: AgedMESH: Middle AgedMESH: RiskHazard ratioAtrial fibrillationVenous ThromboembolismGeneral MedicineMESH: Follow-Up StudiesMiddle AgedIntention to Treat Analysis3. Good healthPulmonary embolismMESH: International Normalized RatioMESH: beta-AlanineMESH: Young AdultAnesthesiaFemaleMESH: Hemorrhagemedicine.drugAdultRiskAdolescentHemorrhageLower riskPlaceboDabigatranDabigatran Venous ThromboembolismYoung Adult03 medical and health sciencesmedicineHumansInternational Normalized RatioAgedMESH: AdolescentIntention-to-treat analysisMESH: Humansbusiness.industryWarfarinMESH: Adultmedicine.diseaseMESH: MaleMESH: Recurrencebeta-AlanineBenzimidazolesWarfarinbusinessMESH: BenzimidazolesVenous thromboembolismMESH: FemaleFollow-Up Studies
researchProduct

Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry

2019

BACKGROUND: Women are more susceptible than men to several forms of pulmonary hypertension, but have better survival. Sparse data are available on chronic thromboembolic pulmonary hypertension (CTEPH). METHODS: We investigated sex-specific differences in the clinical presentation of CTEPH, performance of pulmonary endarterectomy (PEA), and survival. RESULTS: Women constituted one-half of the study population of the European CTEPH registry (N = 679) and were characterized by a lower prevalence of some cardiovascular risk factors, including prior acute coronary syndrome, smoking habit, and chronic obstructive pulmonary disease, but more prevalent obesity, cancer, and thyroid diseases. The med…

Malecardiovascular risk factorsAcute coronary syndromemedicine.medical_specialtyHypertension Pulmonary2720 Hematologypulmonary endarterectomyvenous thromboembolism610 MedizinChronic thromboembolic pulmonary hypertension610 Medicine & healthEndarterectomy030204 cardiovascular system & hematologyPulmonary Arterysurvivalchronic thromboembolic pulmonary hypertension03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInterquartile rangeInternal medicine610 Medical sciencesmedicineHumanssexRegistriesbusiness.industry10031 Clinic for AngiologyHazard ratioHematologyMiddle Agedmedicine.diseasePulmonary hypertensionObesityConfidence intervalmedicine.anatomical_structureChronic DiseasePopulation studyFemalebusinessPulmonary EmbolismArtery
researchProduct

International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists

2019

Introduction and objectives: Heart failure patients with nonvalvular atrial fibrillation (NVAF) on treatment with vitamin K antagonists (VKA) often have suboptimal international normalized ratio (INR) values. Our aim was to evaluate the association between INR values at admission due to acute heart failure and mortality risk during follow-up. Methods: In this observational study, we retrospectively assessed INR on admission in 1137 consecutive patients with acute heart failure and NVAF who were receiving VKA treatment. INR was categorized into optimal values (INR = 2-3, n = 210), subtherapeutic (INR 3, n = 267). Because INR did not meet the proportional hazards assumption for mortality, res…

Maleendocrine systemmedicine.medical_specialtyTime FactorsVitamin KHeart failure030204 cardiovascular system & hematologyVitamin kRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeCause of DeathThromboembolismhealth services administrationMean Survival TimeInternal medicineAtrial FibrillationmedicineHumansheterocyclic compoundsInternational Normalized Ratiocardiovascular diseasesInternational normalized ratioNormal rangeAgedRetrospective StudiesHeart Failurebusiness.industryIncidencefungiAnticoagulantsAtrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationSurvival RateSpainHeart failureAcute DiseaseCardiologyFemaleObservational studybusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct